Abstract
Clinical registry allows you to present, as in the Czech Republic served preparations, which are set reimbursement for the treatment of NSCLC in pneumoonkologických centers. They are bevacizumab, erlotiniob, gefitinib, pemetrexed.
Basic data of patients treated with above mentioned preparations are entered Tulung registry, which is a common project of the Czech Pneumological Phthiseological and Society, Czech Oncology Society and the Institute biostistatistiky and Analyses, Masaryk University in Brno.